Janux Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held on June 11, 2026. As of the record date of April 17, 2026, there were 60,961,546 shares of common stock outstanding, with 53,744,922 shares present virtually or by proxy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders voted on three proposals with the following outcomes:
- Proposal 1: Election of Directors
- Natasha Hernday: Elected with 42,850,103 votes for, 4,519,796 withheld, and 6,375,023 broker non-votes.
- Eric Dobmeier: Elected with 46,279,387 votes for, 1,090,512 withheld, and 6,375,023 broker non-votes.
- Proposal 2: Ratification of Independent Auditor
- Ernst & Young LLP was ratified for the fiscal year ending December 31, 2026.
- Results: 53,560,969 votes for, 113,446 against, and 70,507 abstentions.
- Proposal 3: Advisory Vote on Executive Compensation
- Stockholders approved the compensation of named executive officers on a non-binding basis.
- Results: 42,749,182 votes for, 4,574,376 against, 46,341 abstentions, and 6,375,023 broker non-votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation of the new Class II directors' tenure until the 2029 Annual Meeting.
- Verification of the high level of broker non-votes (6,375,023) on director elections and executive compensation.
- Confirmation that Ernst & Young LLP remains the independent auditor for the 2026 fiscal year.
- Review of the Proxy Statement for details on the executive compensation package approved in Proposal 3.